Chymotrypsin powder 10 mg bottle №10

Description

Packaging

10 bottles.

Mechanism of action

Chymotrypsin is a proteolytic enzyme preparation derived from the pancreas of cattle.
Hydrolyzes proteins and peptones to form relatively low molecular weight peptides, cleaves bonds formed by aromatic amino acid residues (tyrosine, tryptophan, phenylalanine, methionine).
In medical practice, the use of chymotrypsin is based on the specific peculiarities of cleaving necrotic tissue and fibrinous formations, thinning viscous secrets and exudates, and, when administered intramuscularly, have an anti-inflammatory effect.

Indications and usage

- Suppressive diseases of the respiratory system: tracheitis, bronchitis, bronchiectasis, pneumonia, lung abscesses, atelectasis, exudative pleurisy, bronchial asthma.
- In the treatment of burns, pressure sores, purulent wounds, thrombophlebitis.
- In ophthalmology: with fresh extensive thrombosis of the central retinal vein, acute obstruction of the central artery of the retina, opacities of the vitreous traumatic and inflammatory origin, extraction of cataracts.
- In otolaryngology: with purulent sinusitis, subacute laryngotracheitis, after tracheostomy to facilitate the removal of thick viscous exudate, with acute, subacute, purulent, chronic otitis media and eustachitis with viscous exudate.

Contraindications

- Hypersensitivity to chymotrypsin.
- Malignant neoplasms.
- Pulmonary tuberculosis (open form).
- Chronic heart failure II - III degree.
- Dystrophy and cirrhosis.
- Viral hepatitis.
- Pancreatitis.
- Hemorrhagic diathesis.
- Emphysema of the lungs with respiratory failure.
It should not be injected into the bleeding cavity, applied to the ulcerated surface of malignant tumors in order to avoid the spread of the malignant process.
With caution in the empyema of tuberculous ethnology (pleural resorption may in some cases contribute to the development of bronchopleural fistula).

Dosage and administration

For intramuscular administration, immediately before use, 0.005 g of the drug is dissolved in 1-2 ml of sterile 0.9% sodium chloride solution or 0.5-2% procaine solution. The course of treatment is 6-15 injections.
For respiratory diseases: the drug is used intramuscularly in doses of 5-10 mg per day for 10-12 days, it may be combined with the use of chymotrypsin aerosol in 5% aqueous solution in an amount of 3-4 ml. After 7-10 days, the treatment can be repeated.
In the treatment of burns and bedsores: Chymotrypsin at a dose of 20 mg is dissolved in 20 ml of a 0.25% solution of procaine and a thin needle is injected under a scab with several injections.
In the treatment of purulent wounds: purulent wound surfaces impose sterile wipes moistened with a solution of 0.025-0.05 g of chymotrypsin in 10-50 ml of a 025% procaine solution for 8 hours. For the treatment of purulent wounds, intramuscular injections of the drug are combined with local treatment of the wound with tampons moistened with a 5% aqueous solution of chymotrypsin.
With thrombophlebitis: The drug is administered intramuscularly at 5-10 mg daily for 7-10 days.
For cataract extraction: Chymotrypsin at a dilution of 1: 5000 is introduced into the posterior chamber of the eye, followed by washing the anterior chamber of the eye with a 0.9% solution of sodium chloride 4 minutes after drug administration.
In the treatment of thrombosis of the central vein of the retina, acute obstruction of the central artery of the retina: Chymotrypsin is administered subconjunctivally at 0.2 ml of a 5% solution prepared in 1% procaine solution, 1-2 times a week.
With sinusitis: the drug is introduced into the appropriate cavity in the amount of 5-10 mg in 3-5 ml of 0.9% sodium chloride solution after puncture and washing the cavity.
With otitis media: instill into the ear 0.5-1 ml of 0.1% solution of chymotrypsin in 0.9% sodium chloride solution.
When micro-operations on the ear to soften fibrinous formations in the middle ear: during surgery, a 0.1% chymotrypsin solution is injected into the cavity. Simultaneously, chymotrypsin should be administered intramuscularly at 2.5-5 mg 1-2 times a day.
The drug is diluted in 1-2 ml of a 0.25-0.5% solution of Novocaine or 0.9% sodium chloride solution.

Adverse reactions

Allergic reactions may occur. Increase in body temperature to subfebrile. Tachycardia. After inhalation, irritation of the mucous membranes of the upper respiratory tract, hoarseness of the voice is occasionally observed. Subconjunctival administration may cause irritation and swelling of the conjunctiva; in such cases, it is recommended to reduce the concentration of the applied solution. After intramuscular injection, pain and hyperemia may occur at the injection site.

Storage conditions

Store in a dry, dark place at a temperature not exceeding + 10 ° C.